CENCORA INC
CORNYSETrading Snapshot
- Day Range
- $320.06 β $327.43
- 52-Week Range
- $244.82 β $377.54
- Volume (shares)
- 1,076,734
- Avg Volume (shares)
- β
- Shares Outstanding
- 190.8M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $321.33B
- Last Q Revenue
- $84.75B
- P/E Ratio
- 24.0
- P/S Ratio
- 0.2x
- EPS (TTM)
- $13.45
- Dividend Yield
- 0.74%
- Dilution (1yr)
- +0.1%
CENCORA INC
CORAbout CENCORA INC
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network
COR's $2.4B acquisition of AON aims to expand its oncology services platform, strengthen community cancer care and support long-term growth.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Surgery Partners, Inc. (Nasdaq β SGRY), Range Resources Corporation (NYSE β RRC), American Oncology Network, Inc. (OTCQX β AONC), Utz Brands, Inc. (NYSE β UTZ)
BALA CYNWYD, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq β PASG), American Oncology Network, Inc. (OTCQX β AONC), Utz Brands, Inc. (NYSE β UTZ), Finward Bancorp (Nasdaq β FNWD)
BALA CYNWYD,Β Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith

Cencora to acquire American Oncology Network in $2.4 billion deal
Cencora to acquire American Oncology Network in $2.4 billion deal

Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (βAONβ) (OTCQX: AONC), a physician-led netw